These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 31636355)

  • 1. Meta-analysis of the associations of CYP2B6-516G>T polymorphisms with efavirenz-induced central nervous system side effects and virological outcome in HIV-infected adults.
    Cheng L; Wang Y; Li X; Feng W; Weng B; Yuan Q; Xia P; Sun F
    Pharmacogenomics J; 2020 Apr; 20(2):246-259. PubMed ID: 31636355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2B6 Genetic Polymorphisms, Depression, and Viral Suppression in Adults Living with HIV Initiating Efavirenz-Containing Antiretroviral Therapy Regimens in Uganda: Pooled Analysis of Two Prospective Studies.
    Chang JL; Lee SA; Tsai AC; Musinguzi N; Muzoora C; Bwana B; Boum Y; Haberer JE; Hunt PW; Martin J; Bangsberg DR; Kroetz DL; Siedner MJ
    AIDS Res Hum Retroviruses; 2018 Nov; 34(11):982-992. PubMed ID: 29973058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic-Pharmacogenetic Model of HIV-infected Patients in Thailand.
    Chaivichacharn P; Avihingsanon A; Manosuthi W; Ubolyam S; Tongkobpetch S; Shotelersuk V; Punyawudho B
    Clin Ther; 2020 Jul; 42(7):1234-1245. PubMed ID: 32451120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapy.
    Lee KY; Lin SW; Sun HY; Kuo CH; Tsai MS; Wu BR; Tang SY; Liu WC; Chang SY; Hung CC
    PLoS One; 2014; 9(2):e88497. PubMed ID: 24551111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.
    Sinxadi PZ; Leger PD; McIlleron HM; Smith PJ; Dave JA; Levitt NS; Maartens G; Haas DW
    Br J Clin Pharmacol; 2015 Jul; 80(1):146-56. PubMed ID: 25611810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.
    Kwara A; Lartey M; Sagoe KW; Rzek NL; Court MH
    Br J Clin Pharmacol; 2009 Apr; 67(4):427-36. PubMed ID: 19371316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sleep quality in efavirenz-treated Chinese HIV patients - comparing between GT and GG genotype of CYP2B6-516 G/T polymorphisms.
    Lee SS; To KW; Lee MP; Wong NS; Chan DP; Li PC; Cheung SW; Chan RC
    Int J STD AIDS; 2014 Mar; 25(3):193-200. PubMed ID: 23970651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma levels of efavirenz and frequency of the CYP2B6 516G>T polymorphism in people living with HIV-1 in Mexico.
    Ortíz-Rodríguez MA; Oaxaca-Navarro J; Patiño-Camacho SI; García-Jiménez S; Déciga-Campos M; Martínez-Salazar MF
    Pharmazie; 2022 Jun; 77(6):191-195. PubMed ID: 35751161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms : a substudy of the ANRS ALIZE trial.
    Gallien S; Journot V; Loriot MA; Sauvageon H; Morlat P; Reynes J; Reliquet V; Chêne G; Molina JM;
    HIV Med; 2017 Sep; 18(8):537-545. PubMed ID: 28145050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.
    Haas DW; Kwara A; Richardson DM; Baker P; Papageorgiou I; Acosta EP; Morse GD; Court MH
    J Antimicrob Chemother; 2014 Aug; 69(8):2175-82. PubMed ID: 24729586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation.
    Kwara A; Lartey M; Sagoe KW; Xexemeku F; Kenu E; Oliver-Commey J; Boima V; Sagoe A; Boamah I; Greenblatt DJ; Court MH
    J Clin Pharmacol; 2008 Sep; 48(9):1032-40. PubMed ID: 18728241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Occurrence of CYP2B6 516G>T polymorphism in patients with ARV-associated hepatotoxicity.
    Singh H; Lata S; Dhole TN; Gangakhedkar RR
    Mol Genet Genomic Med; 2019 Apr; 7(4):e00598. PubMed ID: 30864294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients.
    Sarfo FS; Zhang Y; Egan D; Tetteh LA; Phillips R; Bedu-Addo G; Sarfo MA; Khoo S; Owen A; Chadwick DR
    J Antimicrob Chemother; 2014 Feb; 69(2):491-9. PubMed ID: 24080498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically defined subgroups of mother-infant pairs: an observational study.
    Olagunju A; Bolaji O; Amara A; Waitt C; Else L; Adejuyigbe E; Siccardi M; Back D; Khoo S; Owen A
    Clin Infect Dis; 2015 Aug; 61(3):453-63. PubMed ID: 25882300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of cytochrome P450 2B6 and constitutive androstane receptor genetic variation on Efavirenz plasma concentrations among HIV patients in Kenya.
    Ngayo MO; Oluka M; Kwena ZA; Bulimo WD; Okalebo FA
    PLoS One; 2022; 17(3):e0260872. PubMed ID: 35235559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2B6 genotypes and early efavirenz-based HIV treatment outcomes in Botswana.
    Gross R; Bellamy SL; Ratshaa B; Han X; Vujkovic M; Aplenc R; Steenhoff AP; Mosepele M; Moorthy G; Zuppa AF; Strom BL; Bisson GP
    AIDS; 2017 Sep; 31(15):2107-2113. PubMed ID: 28692529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationships of ABCB1 3435C>T and CYP2B6 516G>T with high-density lipoprotein cholesterol in HIV-infected patients receiving Efavirenz.
    Mahungu TW; Nair D; Smith CJ; Egan D; Youle M; Johnson MA; Khoo SH; Back DJ; Owen A
    Clin Pharmacol Ther; 2009 Aug; 86(2):204-11. PubMed ID: 19474786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment.
    von Braun A; Castelnuovo B; Ledergerber B; Cusato J; Buzibye A; Kambugu A; Fehr J; Calcagno A; Lamorde M; Sekaggya-Wiltshire C
    J Antimicrob Chemother; 2019 Jan; 74(1):135-138. PubMed ID: 30239753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brief Report: CYP2B6 516G>T Minor Allele Protective of Late Virologic Failure in Efavirenz-Treated HIV-Infected Patients in Botswana.
    Vujkovic M; Bellamy SL; Zuppa AF; Gastonguay M; Moorthy GS; Ratshaa BR; Han X; Steenhoff AP; Mosepele M; Strom BL; Aplenc R; Bisson GP; Gross R
    J Acquir Immune Defic Syndr; 2017 Aug; 75(4):488-491. PubMed ID: 28481785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenomics and pharmacokinetics of efavirenz 400 or 600 mg in 184 treatment-naive HIV-infected patients in China.
    Chen R; Chen J; Xun J; Hu Z; Huang Q; Zhang R; Steinhart C; Shen Y; Liu L; Lu H
    Pharmacogenomics; 2020 Aug; 21(13):945-956. PubMed ID: 32838647
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.